KholleKhokk

VIR - the fundamental play

Long
NASDAQ:VIR   Vir Biotechnology, Inc.
There is something that market is wrong about. The VIR and its blockbuster drug. This drug earns $1-1.5B per Q.
+ they are clinical stage company with Huuge innovative pipeline in HBV and HIV - treatments and VACCINES!

And market prices them like @#$! while they will earn around their own 1x market cap in 2022 and will sit with so much cash, that the current market cap of a company is HUGE misspricing.

Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.